hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06287736, orgStudyIdInfo id: 2023H0386, briefTitle: Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Ohio State University, class: OTHER, collaborators name: Neuright, Inc., descriptionModule briefSummary: This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers., conditionsModule conditions: Diabetic Peripheral Neuropathy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Spinal Cord Stimulator Implantation (SCS), outcomesModule primaryOutcomes measure: Change in Pain level, primaryOutcomes measure: Change in Diabetic Peripheral Neuropathy (DPN) Pain using the Neuropathic pain diagnostic questionnaire (DN4), primaryOutcomes measure: Change in PROMIS quality of life in relation to pain level, secondaryOutcomes measure: change in neuropathic symptoms using Michigan Neuropathy Screening instrument, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Ohio State University Wexner Medical Center, city: Columbus, state: Ohio, zip: 43210, country: United States, contacts name: Uchechi Okafor, role: CONTACT, phone: 614-366-3439, email: Uchechi.Okafor@osumc.edu, contacts name: Brian Dalm, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Kristy Townsend, PhD, role: SUB_INVESTIGATOR, contacts name: Magdalena Blaszkiewicz, PhD, role: SUB_INVESTIGATOR, contacts name: Miriam Freimer, MD, role: SUB_INVESTIGATOR, contacts name: Bakri Elsheikh, MD, role: SUB_INVESTIGATOR, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06287723, orgStudyIdInfo id: RECHMPL23_0297, briefTitle: French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2028-10-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, descriptionModule briefSummary: Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.FRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project., conditionsModule conditions: Colorectal Cancer, conditions: Liver Metastases, conditions: Stage IV Colorectal Cancer, conditions: Minimal Residual Disease, conditions: Liquid Biopsy, conditions: ctDNA, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Blood sample/Liquid biopsy, outcomesModule primaryOutcomes measure: 3-year disease free survival, secondaryOutcomes measure: Sensitivity (Se) of the ctDNA diagnostics, secondaryOutcomes measure: Specificity (Sp) of the ctDNA diagnostics, secondaryOutcomes measure: Positive predictive value of the ctDNA diagnostics, secondaryOutcomes measure: Negative predictive value of the ctDNA diagnostics, secondaryOutcomes measure: Area under the curve of the ctDNA diagnostics, secondaryOutcomes measure: Time to clinical recurrence, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Time to molecular recurrence, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06287710, orgStudyIdInfo id: CHUBX 2023/32, briefTitle: Fluid Responsiveness Evaluation by a Non-invasive Method in Children, Extended to PREterm Infants - FRENCH-PREMA, acronym: FRENCH-PREMA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-17, primaryCompletionDateStruct date: 2024-11-17, completionDateStruct date: 2025-04-17, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University Hospital, Bordeaux, class: OTHER, descriptionModule briefSummary: In this study, the investigators aim to validate a non-invasive marker of fluid-responsiveness in preterm infants (term below 37 gestational week) with acute circulatory failure based on standardized abdominal compression. This would allow physicians to identify which patient could benefit from a fluid expansion, thus avoiding a potentially useless or even dangerous fluid expansion, leading to fluid overload. To this end, the investigators will evaluate the diagnostic accuracy (sensitivity and specificity) of stroke volume variation induced by standardized abdominal compression for the diagnosis of fluid responsiveness (based on the gold-standard test: significant increase in cardiac index after fluid expansion)., conditionsModule conditions: Premature Baby 26 to 32 Weeks, conditions: Premature Baby 33 to 36 Weeks, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment)., outcomesModule primaryOutcomes measure: Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of the index test (ΔSVi-AC) for the diagnosis of fluid responsiveness,, secondaryOutcomes measure: Diagnostic accuracy of the SAV mean and the ΔPeak for the diagnosis of fluid responsiveness, eligibilityModule sex: ALL, minimumAge: 1 Minute, maximumAge: 5 Months, stdAges: CHILD, contactsLocationsModule locations facility: Bordeaux Hospital University, status: RECRUITING, city: Bordeaux, zip: 33076, country: France, contacts name: Sophie CRAMAREGEAS, MD, role: CONTACT, phone: 0557821269, contacts name: sophie.cramaregeas@chu-bordeaux.fr, role: CONTACT, geoPoint lat: 44.84044, lon: -0.5805, hasResults: False
protocolSection identificationModule nctId: NCT06287697, orgStudyIdInfo id: LOA/RAP/2019/20, briefTitle: Energy Expenditure and Body Composition of Infants and Young Children (6-24 Months Old) in Asia, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2020-01-21, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Mahidol University, class: OTHER, collaborators name: International Atomic Energy Agency, collaborators name: National Institute of Nutrition, Vietnam, collaborators name: Faculty of Medicine, University of Ruhuna, Sri Lanka, collaborators name: Pakistan Institute of Nuclear Science and Technology (PINSTECH), collaborators name: Food and Nutrition Research Institute, Philippines, collaborators name: FAO, descriptionModule briefSummary: This project is a collaboration between International Atomic Energy Agency (IAEA), FAO Regional Office for Asia and The Pacific, and Mahidol University, Thailand to carry out the study on doubly-labeled water for assessment of total energy expenditure and body composition among infants and young children aged 6-23 months old. Thailand conducted a longitudinal study with participation from 4 other countries, namely, Pakistan, Philippines, Sri Lanka and Vietnam, in undertaking the same assessments in a cross-sectional design., conditionsModule conditions: Energy Expenditure, conditions: Body Composition, conditions: Infants and Young Children, conditions: Infant and Young Child Feeding, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 391, type: ACTUAL, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Total Energy Expenditure, primaryOutcomes measure: Body composition, secondaryOutcomes measure: Weight, secondaryOutcomes measure: Length, secondaryOutcomes measure: Head circumference, secondaryOutcomes measure: Mid-upper arm circumference, secondaryOutcomes measure: Triceps skinfold thickness, secondaryOutcomes measure: Subscapular skinfold thickness, secondaryOutcomes measure: Infant and Young Child Feeding (IYCF), secondaryOutcomes measure: Dietary intake, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 24 Months, stdAges: CHILD, contactsLocationsModule locations facility: Institute of Nutrition, Mahidol University, city: Salaya, state: Nakhon Pathom, zip: 73170, country: Thailand, geoPoint lat: 13.802, lon: 100.32111, hasResults: False
protocolSection identificationModule nctId: NCT06287684, orgStudyIdInfo id: ESICM-22, briefTitle: Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis, acronym: MENDSEP, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-13, primaryCompletionDateStruct date: 2025-12-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Mater Dei Hospital, Malta, class: OTHER, collaborators name: European Society of Intensive Care Medicine, collaborators name: University of Malta, descriptionModule briefSummary: Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular endotypes, or subclasses, with important clinical implications. Classifying sepsis patients as molecular endotypes revealed that a poor prognosis endotype was characterized by immunosuppression and septic shock. Against this backdrop, the study hypothesis is that a poor prognosis for sepsis is defined by a molecular endotype reflecting impaired innate immune and endothelial barrier integrity in the primary anatomical site of infection., conditionsModule conditions: Sepsis, conditions: Septic Shock, conditions: Pneumonia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 132, type: ESTIMATED, armsInterventionsModule interventions name: Blood transcriptomics and BAL protein profiling, outcomesModule primaryOutcomes measure: Patient stratification as transcriptomic endotypes, primaryOutcomes measure: Lung endothelial barrier integrity, secondaryOutcomes measure: Survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mater Dei hospital, Intensive Care Unit, status: RECRUITING, city: Imsida, zip: MSD2080, country: Malta, contacts name: Carmel Abela, role: CONTACT, phone: +35625450000, email: carmel.c.abela@gov.mt, geoPoint lat: 35.8925, lon: 14.48278, hasResults: False
protocolSection identificationModule nctId: NCT06287671, orgStudyIdInfo id: COCO, briefTitle: Colorectal Omics and ofCS Proteoglycans, acronym: COCO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2032-12, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Claus Anders Bertelsen, PhD, MD, class: OTHER, collaborators name: Viborg Regional Hospital, descriptionModule briefSummary: This observational study aims to test proteomics, metabolomics and proteoglycans as predictors of postoperative complications after colorectal surgery and as biomarkers of colorectal cancer.The main questions to answer are:* can these biomarkers predict anastomotic leakages* can these biomarkers predict recurrence after colorectal cancer* can these biomarkers be used as diagnostic tests for colorectal cancer* can these biomarkers be identified in the tumorParticipants will undergo elective colorectal resection or stoma closure., conditionsModule conditions: Colorectal Cancer, conditions: Diverticulitis, Colonic, conditions: Inflammatory Bowel Diseases, conditions: Stoma Colostomy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Colorectal resection or stoma closure, outcomesModule primaryOutcomes measure: Rate of anastomotic leakage diagnosed by CT-scan or reoperation, primaryOutcomes measure: Rate of major postoperative complications, primaryOutcomes measure: Short-term mortality, primaryOutcomes measure: Recurrence after colorectal cancer, primaryOutcomes measure: Diagnostic value of omics and other biomarkers detecting colorectal cancer, primaryOutcomes measure: Correlation between biomarker in plasma and tissue, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nordsjaellands Hospital, city: Hillerød, zip: 3400, country: Denmark, contacts name: Nanna B Hupfeld, MD, role: CONTACT, phone: +4548292793, email: nanna.baekvang.hupfeld.01@regionh.dk, contacts name: Claus A Bertelsen, PhD, role: CONTACT, phone: +4548295972, email: claus.anders.bertelsen@regionh.dk, geoPoint lat: 55.92791, lon: 12.30081, locations facility: Regionshospitalet Viborg, city: Viborg, zip: 8800, country: Denmark, contacts name: Uffe S Løwe, PhD, role: CONTACT, geoPoint lat: 56.45319, lon: 9.40201, hasResults: False
protocolSection identificationModule nctId: NCT06287645, orgStudyIdInfo id: Retinal Images Dataset, briefTitle: Color Fundus Photograph With Experts Labelling, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-05-12, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Pakistan Council of Scientific and Industrial Research, class: OTHER, collaborators name: Al-Ibrahim Eye Hospital, descriptionModule briefSummary: This trial aims to provide a digital retinal image dataset from Pakistan, graded by three specialists according to the severity of Diabetic Retinopathy. The dataset aims to improve research and patient care., conditionsModule conditions: Retinal Disease, conditions: Diabetic Retinopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 50000, type: ESTIMATED, armsInterventionsModule interventions name: Color Fundus Photography/Non-Mydriatic Opthalmic Cameras, outcomesModule primaryOutcomes measure: Grading Diabetic Retinopathy Severity according to International Clinical Diabetic Retinopathy Severity Scale, primaryOutcomes measure: Grading Diabetic Retinopathy Severity according to Early Treatment of Diabetic Retinopathy Scale, primaryOutcomes measure: Finding inter-rater agreement among the graders, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Al Ibrahim Eye Hospital, status: RECRUITING, city: Karachi, country: Pakistan, contacts name: Ghulam Mustafa, role: CONTACT, email: mustafabme@gmail.com, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06287632, orgStudyIdInfo id: 2024P000451, briefTitle: CPAP in Patients With Severe Obesity After Anesthesia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-11, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, descriptionModule briefSummary: The goal of this study is to compare two continuous positive airway pressure (CPAP) settings on heart and lung function in patients with severe obesity after anesthesia. The main questions it aims to answer are:1. Does a recruitment maneuver and CPAP set to intrathoracic pressure (ITP) improve cardiopulmonary function compared to standard CPAP settings in patients with severe obesity after anesthesia?2. Does the location of adipose tissue influence the response to CPAP settings in patients with severe obesity after anesthesia?Participants will undergo monitoring of their intrathoracic pressure using an esophageal catheter. In the recovery area after anesthesia, participants will receive two CPAP settings, each for 20 minutes.* Intervention 1: Recruitment maneuver and CPAP will set to the level of intrathoracic pressure* Intervention 2: CPAP set to home settings (if OSA is present) or between 8-10 cmH20 (if OSA is not present)., conditionsModule conditions: Obesity, Abdominal, conditions: Anesthesia Morbidity, conditions: Apnea, Obstructive Sleep, conditions: Atelectases, Postoperative Pulmonary, conditions: Ventilator Lung, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Recruitment/ITP-CPAP (Intervention A), interventions name: Standard CPAP (Intervention B), interventions name: Atmospheric Pressure, outcomesModule primaryOutcomes measure: End expiratory lung impedance, secondaryOutcomes measure: Regional lung ventilation, secondaryOutcomes measure: Right ventricular function, secondaryOutcomes measure: Mean pulmonary artery pressure, secondaryOutcomes measure: Inspiratory effort, secondaryOutcomes measure: Abdominal muscle thickness, secondaryOutcomes measure: Respiratory rate, secondaryOutcomes measure: Oxygen saturation, secondaryOutcomes measure: Systemic blood pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06287606, orgStudyIdInfo id: CTP0302, briefTitle: A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-08-29, primaryCompletionDateStruct date: 2024-01-17, completionDateStruct date: 2024-05-14, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Taejoon Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A prospective randomized study compared to the active control. Researchers compare colon cleansing in patients undergoing colonoscopy, conditionsModule conditions: Bowel Preparation, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 161, type: ACTUAL, armsInterventionsModule interventions name: CTP0302-A, interventions name: CTP0302-B, interventions name: Conventional OST, outcomesModule primaryOutcomes measure: Ratio of subjects With successful Bowel Cleansing, secondaryOutcomes measure: Each segments ratio of subject with successful Bowel Cleansing, otherOutcomes measure: Comparison of Acute gastropathy probability score, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taejoon Pharmaceutical Co., Ltd., city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06287593, orgStudyIdInfo id: NeoLiq, briefTitle: The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, descriptionModule briefSummary: This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients., conditionsModule conditions: EGF-R Positive Non-Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: ctDNA monitoring, outcomesModule primaryOutcomes measure: the rate of major pathological response (MPR), secondaryOutcomes measure: the rate of pathological complete response (pCR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False